Kiyaros AS 10 Capsule is a combination medication containing Rosuvastatin 10 mg and Aspirin 75 mg, indicated for the management of cardiovascular risk in patients with hyperlipidemia and those requiring antiplatelet therapy. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels by inhibiting cholesterol biosynthesis in the liver, thereby reducing the risk of atherosclerosis and related cardiovascular events. Aspirin, an antiplatelet agent, irreversibly inhibits cyclooxygenase-1 (COX-1), leading to decreased thromboxane A2 production and subsequent inhibition of platelet aggregation, which helps prevent thrombus formation. The combination of these two agents provides a synergistic effect in reducing the risk of myocardial infarction, stroke, and other cardiovascular complications in high-risk patients. Kiyaros AS 10 Capsule is typically prescribed for patients with established coronary artery disease, previous myocardial infarction, or those at high risk due to multiple risk factors. It should be used under medical supervision with regular monitoring of lipid profiles, liver function tests, and bleeding parameters. Caution is advised in patients with hepatic impairment, active bleeding disorders, or hypersensitivity to either component. Adherence to prescribed dosage and lifestyle modifications enhances therapeutic outcomes.